NEJM study shows Votrient's benefits in Kidney Cancer
Results from a Phase III trial of 1,100 metastatic Kidney Cancer patients comparing Votrient (pazopanib), from Glaxo Smith Kline, with Sutent (sunitinib), are published in the August 22 issue of the New England Journal of Medicine. Median time before the cancer progressed was similar: 8.4 months for Votrient and 9.5 months for sunitinib. Median overall survival was also comparable: 28.4 months for Votrient vs 29.3 months for sunitinib.
However Votrient was rated superior on 11 or 14 measures of quality of life. In addition, Votrient patients had fewer phone consultations with doctors and visited ER less frequently. See: "Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma" Robert J. Motzer et al. N Engl J Med 2013, 369, 722-31. DOI: 10.1056/NEJMoa1303989
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins